Prevention of ischemic stroke in clinical practice: a role of internists and general practitioners

Maciej Niewada, Anna Członkowska

Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
2nd Neurological Department, Institute of Psychiatry and Neurology, Warsaw, Poland

KEY WORDS
ischemic stroke, prevention, risk factors, stroke sequelae, transient ischemic attack

ABSTRACT
Stroke constitutes a substantial clinical and socio-economic burden. It is currently the third cause of death worldwide and results in mortality or disability in every third patient at the end of the first year following an acute cerebrovascular event. Although in-hospital mortality rates in stroke patients have decreased, prevention and cardiovascular risk control remain critical for improving the prognosis and reducing stroke burden worldwide. The definitions of stroke and transient ischemic attack (TIA) have been recently modified following the findings from neuroimaging and thrombolysis research. Both stroke and TIA are recurrent and preventable disorders. Both patients with stroke and those with TIA require prompt clinical workup, risk assessment, and appropriate management because the risk of recurrence, stroke, and coronary events is significant. The 5 most common cardiovascular risk factors (high blood pressure, smoking, abdominal obesity, diet, and lack of physical activity) are responsible for 80% of the cases. Stroke prevention involves lifestyle modification and specific treatment. Secondary prevention of ischemic stroke involves early treatment (antiplatelets and carotid interventions) and long-term management including lifestyle changes, antihypertensive therapy, antiplatelets, antithrombotic drugs in patients with atrial fibrillation, and the use of statins and other lipid-lowering drugs. Stroke patients are at risk of depression, dementia, epilepsy, and other complications that also require targeted treatment.

Stroke and transient ischemic attack as clinical challenges and preventable diseases
Almost 40 years ago, the World Health Organization (WHO) defined stroke as a “neurological deficit of cerebrovascular cause that persists beyond 24 hours or is interrupted by death within 24 hours”. Accordingly, symptoms lasting less than 24 hours indicate transient ischemic attack (TIA). Until recently, TIA and mild stroke were not managed as acute states and were not considered to require quick diagnostic workup and treatment. However, according to current clinical practice, both stroke and TIA need special attention owing to a risk of fully symptomatic stroke and neurological deficit as well as effective prevention and treatment that is widely available and recommended. Recently, the classic definition of TIA based on arbitrary symptom duration of less than 24 hours has been questioned. Imaging studies have shown restricted diffusion lesions at clinically significant sites in every third patient with traditional 24-hour TIA. An updated definition of stroke has incorporated clinical and tissue criteria with less emphasis on time span. Currently, stroke, and not TIA, should be diagnosed in patients with symptoms lasting less than 24 hours and either new lesions corresponding to clinical signs or thrombolysis-induced full recovery regardless of imaging findings.

Burden of stroke
Stroke constitutes a substantial clinical and socio-economic burden. Currently, it is the third cause of death worldwide (in the upper-middle-income countries, as defined by the WHO, stroke ranks even second, exceeding ischemic heart disease). Annually, about 15 million people worldwide suffer from stroke, of whom one-third die in the first year. Of 30 million stroke survivors, half becomes permanently disabled. In the United Kingdom, around 20% of all acute
hospital beds and 25% of long-term beds are occupied by stroke patients. As age is the major non-modifiable risk factor of stroke (the risk of stroke more than doubles for each successive decade after the age of 55 years), population aging may be associated with a growing number of individuals at risk. Although in the last decades numerous interventions for acute stroke have been successfully introduced (e.g., stroke unit-based treatment, thrombolysis with alteplase, decompressive craniectomy in extensive middle cerebral artery stroke, or early and intensive rehabilitation), still both primary and secondary prevention is crucial in limiting the burden of cerebrovascular diseases.

**Stroke epidemiology and prevention** Both stroke and TIA are recurrent and preventable disorders. It should be stressed that treatment of acute ischemic stroke is still a challenge. Although in-hospital mortality has improved in developed countries, an overall long-term prognosis remains poor. Thus, prevention is crucial in limiting the burden of cerebrovascular events. WHO studies revealed an up to 10-fold difference in age- and sex-adjusted mortality rates and burden among countries, with considerably higher rates in low-income countries compared with those in high-income ones. Stroke incidence has declined by over 40% in the past 4 decades in high-income countries (further improvement seems to be challenging owing to population aging) while, over the same period, it has doubled in low- and middle-income countries owing to poor risk factor control. Effective prevention and cardiovascular risk control substantially contribute to better prognosis of stroke patients in high-income countries.

The highest risk of a recurrent cerebrovascular event is observed in the first month (4%) and year (12%) after stroke. In subsequent years, the risk is still substantial (a mean of 5% per year). Recurrent strokes still account for 25% to 30% of all strokes and represent unsuccessful secondary prevention.

A 90-day risk of stroke after a TIA has been reported to be 17%, with the highest risk observed in the first week (5%–10%). Thus, for internists and general practitioners, it is crucial to stratify patients with TIA into a low-, moderate-, or high-risk group of early recurrent stroke. In targeting high-risk patients, the ABCD2 score was proposed in 2007 as a modified version of the ABCD score of 2005 (Table 1). Recently, double TIsas (the presence of ≥2 TIA symptoms within 7 days) have been added to the ABCD2 score to form the ABCD3 score, which has been further developed into ABCD3-I by adding the presence of abnormal findings on neuroimaging. Neuroimaging in the ABCD3 score may facilitate prediction of long-term stroke risk after TIA. As neuroimaging can initially be hardly available, the use of either the ACBD2 or ABCD3 score is the most convenient in primary care. It should be stressed that the ABCD2 score can be used to stratify risk but not to decide on when to start the treatment, hence all patients with TIA should be immediately assessed irrespective of the ABCD2 score because even patients with lower scores might have treatable conditions, i.e., carotid stenosis or atrial fibrillation (AF). TIA clinics are recommended as acute specialty units dedicated for these patients. In everyday clinical practice, high-risk patients, patients with recurrent TIsas, or those with no access to a quick workup on an outpatient basis need immediate hospital admission.

A comparison of the Oxford Community Stroke Project (1981–1984) and Oxford Vascular Study (2002–2004) showed that the incidence of major stroke after TIA or minor stroke can be substantially reduced (almost by half) with an increased use of preventive treatments and substantial reduction in premorbid risk factors. In addition, other trials on TIA (EXPRESS and SOS-TIA) have demonstrated that immediate workup and prompt implementation of preventive measures can decrease a 90-day risk of stroke by 80%. Primary prevention is aimed at effective control of stroke risk factors, while secondary prevention additionally targets a number of conditions specific for stroke. As for secondary prevention, there is no need to differentiate between stroke and TIA because both require the same management.

**Primary prevention: stroke risk factors** Cerebrovascular diseases share common risk factors with other cardiovascular diseases. Modifiable and nonmodifiable risk factors are presented in Table 2.

The INTERSTROKE study revealed that 80% of strokes are associated with 5 risk factors (high blood pressure, smoking, abdominal obesity, diet, and physical activity). Those factors are additionally associated with 5 more factors (diabetes, alcohol intake, psychosocial stress and depression,

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Predicting the risk of stroke after a transient ischemic attack, ABCD score (max. 7 points)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 points</td>
<td>1 point</td>
</tr>
<tr>
<td>age, y</td>
<td>&lt;60</td>
</tr>
<tr>
<td>blood pressure, mmHg</td>
<td>normal</td>
</tr>
<tr>
<td>clinical symptoms</td>
<td>no speech disturbance and no unilateral (one-sided) weakness</td>
</tr>
<tr>
<td>symptom duration, min</td>
<td>&lt;10</td>
</tr>
<tr>
<td>diabetes</td>
<td>no</td>
</tr>
</tbody>
</table>
cardiac causes, and lipid abnormalities), thus together accounting for 90% of strokes. Those 10 modifiable risk factors contribute the most to stroke risk and should be targeted in clinical practice. This is particularly true for hypertension, which unlike for ischemic heart disease by far more than lipids determines stroke risk, particularly hemorrhagic stroke.16 The above risk factors are used in several prognostic scoring systems, including CHADS2, and CHA2DS2-VASC scores, which are recommended in patients with AF.

### Secondary prevention

#### Treatment and early prevention of acute ischemic stroke

It is important to start prevention early, particularly in acute stroke. Therefore, we discuss a number of treatment options for acute ischemic stroke in the context of internal and general medicine practice. So far, a couple of interventions have been identified to improve early prognosis in patients with ischemic stroke. The first one is stroke unit-based treatment. A Cochrane review of 28 trials confirmed that organized stroke unit care (ie, hospital care provided by nurses, doctors, and therapists who specialize in caring for stroke patients and work as a coordinated multidisciplinary team) is associated with a reduced risk of death, institutionalized care, or dependency. Of note, the patient should be admitted to a stroke unit as quickly as possible to make sure that thrombolysis with alteplase—already confirmed previous findings showing that high-dose naproxen was associated with lower cardiovascular risk than other NSAIDs.

Overused vasoactive and neuroprotective drugs (nicergoline, piracetam, vinpocetin, etc.), although extensively studied and shown to be effective in the animal model, have not been proved beneficial in large translational clinical trials either in acute management of stroke or prevention and treatment of its sequelae.

### Lifestyle modification

Smoking cessation can be supported by behavioral therapy and pharmacological agents (nicotine replacement therapy, bupropion, cytisine, or varenicline).21,22 Alcohol intake should not exceed 2 drinks per day (14 drinks for males and 9 drinks for females weekly). Moderate physical activity such as walking, jogging, cycling, and swimming for 30 minutes to 1 hour 4 to 7 days a week can improve prognosis. Patients with cardiac diseases are advised to participate in medically supervised exercise programs. Body weight reduction is also beneficial; a target body mass index is below 25 kg/m², while a target waist circumference is less than 80 cm for women and less than 94 cm for men. In terms of healthy and balanced diet, fresh fruit, vegetables, dietary and soluble fiber, whole grain, protein from plant sources, dairy products low in saturated fat and cholesterol, as well as daily sodium intake below 2300 mg (the older the patients, the lower the consumption) are recommended.19,20

### Potentially harmful drugs or drugs of unknown efficacy in stroke

Hormone replacement therapy and oral contraceptives increase the risk of stroke. Thus, such treatments should be avoided in patients with cardiovascular diseases, and additionally, oral contraceptives are contraindicated in women aged over 35 years, those who smoke, are obese, or have a history of thromboembolism. Nonsteroidal anti-inflammatory drugs (NSAIDs), apart from acetylsalicylic acid (aspirin), can reduce the antiplatelet effect of aspirin. Therefore, NSAIDs should be administered 8 hours before or 30 minutes after aspirin intake. NSAIDs can also increase blood pressure (decrease the efficacy of antihypertensive agents), contribute to endothelial dysfunction, or impair renal function. The net effect can translate into increased cardiovascular risk, although an increase is rather slight for an individual. The European Medicines Agency has listed coxibs, and recently also diclofenac, as the least safe NSAIDs. A large meta-analysis of individual patient data revealed that of 1000 patients randomized to a coxib or diclofenac arm for a year, 3 more had major vascular events, one of which was fatal, compared with placebo.21 The study also confirmed previous findings showing that nonsteroidal anti-inflammatory drugs (nicergoline, piracetam, vinpocetin, etc.), although extensively studied and shown to be effective in the animal model, have not been proved beneficial in large translational clinical trials either in acute management of stroke or prevention and treatment of its sequelae.

### Table 2

<table>
<thead>
<tr>
<th>Nonmodifiable risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Sex (male)</td>
</tr>
<tr>
<td>Race (African, Hispanic, Asian-Pacific islanders)</td>
</tr>
<tr>
<td>Family history of stroke</td>
</tr>
<tr>
<td>Low birth weight</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Modifiable risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Smoking</td>
</tr>
<tr>
<td>Obesity and diet</td>
</tr>
<tr>
<td>Low physical activity</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Alcohol abuse</td>
</tr>
<tr>
<td>Psychosocial stress and depression</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>High cholesterol</td>
</tr>
<tr>
<td>History of stroke or transient ischemic attack</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
</tr>
<tr>
<td>Carotid artery disease</td>
</tr>
<tr>
<td>Heart failure</td>
</tr>
</tbody>
</table>

### References

1. Owing to a significant risk of early recurrence of stroke (>3%),23 all patients should start aspirin of 100 to 300 mg immediately after the diagnosis
Long-term prevention of ischemic stroke and transient ischemic attack

Long-term prevention should be established on discharge from a stroke unit. Lifestyle modification after stroke is as necessary as before the event, although physical activity should not be too strenuous and adjusted to patient’s abilities.

Antihypertensive therapy

Hypertension is the most important modifiable risk factor. Effective reduction of blood pressure is crucial in stroke prevention. In primary prevention, all standard antihypertensive agents have been reported to be effective. However, recent studies have shown that a visit-to-visit variability in blood pressure is a significant risk factor for stroke and that it can be increased by some antihypertensive drugs, for example, β-blockers, especially non-selective agents.26,31 De Lima et al.32 reported that β-blockers were ineffective in secondary prevention after stroke or TIA, although they claimed that additional studies were needed to confirm their findings. The randomized data for secondary prevention in stroke patients are limited. Based on the PROGRESS trial, all patients after stroke, both ischemic and hemorrhagic, should be offered dual therapy including an angiotensin-converting enzyme inhibitor (or angiotensin II receptor antagonist) and diuretics. Antihypertensive drugs should be selected based on comorbidities. Diuretics and calcium antagonists reduce variability in blood pressure, which was shown to increase cerebrovascular risk.28 Fluctuating blood pressure increases stroke risk independently of the mean blood pressure values, thus blood pressure reduction and avoiding fluctuations represent a treatment target. The optimal time to start hypotensive therapy after stroke has not been determined, but it should generally be started after the first week and before discharge.

In patients with acute ischemic stroke, blood pressure should definitely not be lowered aggressively, and, usually, there is no need for such treatment unless blood pressure exceeds 220/120 mmHg or 185/110 mmHg in patients eligible for thrombolysis therapy. Antihypertensive therapy prior to a cerebrovascular event is usually suspended in acute stroke (it may be continued in patients with mild stroke or TIA with stable blood pressure, but careful monitoring is needed). In general, the evidence on the safety and benefits of antihypertensive drugs in acute stroke is limited.

Gradual and persistent blood pressure lowering in all stroke patients is recommended but special attention should be paid to carotid or vertebrobasilar occlusive disease owing to a possibility of hemodynamic hypoperfusion.30,41 Target systolic blood pressure levels have not been unequivocally established and should be individualized, but it is generally recommended to achieve blood pressure levels lower than 140/90 mmHg and, eventually, 130 mmHg in patients with lacunar stroke.

Antiplatelet drugs

All patients, apart from those eligible for antithrombotic therapy, should be offered antiplatelet drugs following ischemic stroke or TIA, and, most often, they continue aspirin started during hospital stay. Dual antiplatelet therapy with aspirin and clopidogrel over 3 months is a standard treatment in patients after acute coronary syndromes, however, in stroke
patients, it was associated with a higher risk of major or life-threatening bleedings including intracranial ones.\textsuperscript{42} Current guidelines, including those developed by Polish stroke experts, recommend the following evidence-based antiplatelet drugs: aspirin at a daily dose of 50 to 325 mg; clopidogrel at a daily dose of 75 mg; and a combination of aspirin (25 mg) and extended-release dipiridamole (200 mg) twice daily.\textsuperscript{63} Triflusal or cilostazol and less safe ticlopidine, which are hardly available in Poland, might be considered as a second-line alternative.

**Antithrombotic drugs** Because AF is the strongest individual risk factor associated with a mean 5-fold increase in stroke risk and because strokes associated with AF are more disabling, a more aggressive anticoagulation therapy is necessary in this patient group. Currently, all stroke or TIA patients with nonvalvular AF should be offered antithrombotic therapy rather than antiplatelet drugs. Antithrombotic drugs reduced stroke risk roughly by two thirds, while antiplatelets only by about 20%. Dual therapy with aspirin and clopidogrel is twice as effective as antiplatelet monotherapy but is associated with increased bleeding risk. Antithrombotic therapy with vitamin K antagonists (VKAs) or novel oral anticoagulants (NOACs; direct thrombin inhibitor, dabigatran; factor Xa inhibitors, rivaroxaban and apixaban) are effective in either primary or secondary stroke prevention. Based on recent studies, NOACs compared with VKAs consistently reduce the risk of intracranial bleeding and are generally preferred to VKAs, although they are still not reimbursed in Poland.\textsuperscript{44} Patients with creatinine clearance exceeding 25 ml/min, considered unsuitable for VKAs, should be treated with apixaban rather than with aspirin.\textsuperscript{45} Apixaban is also preferred to dabigatran and rivaroxaban in patients at risk of gastrointestinal bleeding.\textsuperscript{46} Combined use of anticoagulants and antiplatelets should be limited to specific conditions (mechanical heart valve, recent acute coronary syndrome, or coronary stenting).\textsuperscript{47}

The overlap of ischemic stroke predictors in CHADS\textsubscript{2} and CHA\textsubscript{DS}\textsubscript{2}-VASc scores and major bleeding in HAS-BLED score make the antithrombotic therapy challenging. The common predictors that are associated more with ischemic events are older age and previous stroke or TIA, while others (hypertension, diabetes, alcohol intake, or renal impairment) do not predict ischemic or hemorrhagic stroke.\textsuperscript{48} The selection of an anticoagulant drug should be individualized based on renal and hepatic function, potential drug interaction, patient preference, tolerability, previous anticoagulation effectiveness and safety, as well as cost. Risk of falls, advanced age, cognitive impairment and dementia, cerebral small vessel disease (manifesting with microbleeds on neuroimaging) do not exclude anticoagulant therapy.

All AF patients with TIA can be offered oral anticoagulation immediately because the bleeding risk, including intracranial hemorrhage, is low. Such treatment should be delayed in stroke patients with the delay depending on the extent of neurological deficit (in patients with severe stroke, it should be started even 2 weeks after stroke). Moreover, it should be stressed that antithrombotic therapy affects thrombolysis in acute ischemic stroke. VKAs are easily monitored with international normalized ratio (INR); thus, a possible bleeding risk and benefit of recombinant plasminogen activator (rtPA) can be assessed. Thrombolysis is not contraindicated when INR is lower than 1.7. The lack of a widely available and consistent anticoagulation-specific monitoring test for NOACs makes rtPA treatment challenging, and, in many cases, treatment must be discontinued. A standard coagulation test does not allow to test the patient for a recent use of NOACs. In patients who are at high risk of stroke and are ineligible for long-term oral anticoagulation, left percutaneous atrial appendage closure (or excision during an open heart surgery) may be considered.\textsuperscript{49} The currently available data are insufficient to establish whether anticoagulation is equivalent or superior to aspirin for secondary stroke prevention in patients with patent foramen ovale (PFO), unless the venous source of embolism is confirmed, which is an indication for a more aggressive therapy (anticoagulation or, if contraindicated, an inferior vena cava filter). For PFO and coexisting deep vein thrombosis, PFO closure by a transcatheter device might be considered.\textsuperscript{50} In patients with cryptogenic stroke, transcatheter closure may be beneficial in reducing the risk of recurrent vascular events when compared with medical treatment, especially in patients with a substantial shunt.\textsuperscript{51}

**Statins and lipid-lowering drugs** In patients with ischemic stroke or TIA, low-density lipoprotein cholesterol levels can be lowered with diet, physical activity, and statins to reach the target level of less than 2 mmol/l (70 mg/dl).\textsuperscript{51,52} Among statins, only atorvastatin was studied specifically in patients after stroke (a subgroup analysis from the Heart Protection Study [HPS] is also available for simvastatin).\textsuperscript{53,54} Atorvastatin at a high daily dose of 80 mg improved outcomes regardless of the baseline lipid levels; thus, statins should be considered in all poststroke patients. However, the benefit started to be evident after 2 years of treatment, and atorvastatin slightly increased the risk of nonfatal hemorrhagic stroke. New lipid-lowering compounds are being introduced into the clinical practice, but currently only a novel drug, ezetimibe, is reimbursed in Poland for poststroke patients who are not reaching the target level of low-density lipoprotein cholesterol.

**Stroke sequelae** Generally, stroke results in mortality and disability in every third patient at the end of the first year following an acute cerebrovascular event. Stroke patients are at risk of depression, dementia, epilepsy, and other complications
TABLE 3  Major short‑term and long‑term complications and sequelae of stroke

<table>
<thead>
<tr>
<th>Type of complication</th>
<th>Epidemiology</th>
<th>Treatment</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>dysphagia</td>
<td>almost 50% of patients with acute stroke; swallowing disorders resolve within a few days and become long‑term complications in 5% of stroke survivors</td>
<td>swallowing screening test; gastric tube in some patients may even reduce the risk of death</td>
<td>increases the risk of aspiration pneumonia</td>
</tr>
<tr>
<td>seizures</td>
<td>5% of patients during a few initial weeks after stroke</td>
<td>diazepam (10–20 mg), lorazepam (4–8 mg), or phenytoin to treat acute seizures</td>
<td>no need for long‑term use of antiepileptic drugs, unless there have been ≥2 seizure episodes that required neurological consultation and possibly chronic antiepileptic treatment</td>
</tr>
<tr>
<td>spasticity and painful muscle spasms</td>
<td>risk depends on the quality of care</td>
<td>physical therapy, muscle relaxant agents, botulinum toxin</td>
<td>spasticity can lead to disability, pain, pressure ulcer</td>
</tr>
<tr>
<td>urinary tract infections</td>
<td>common; on average in every forth patient during the initial 2 months after stroke</td>
<td>antibiotics; proper hydration of patients and avoiding a prolonged use of an intravesical catheter</td>
<td></td>
</tr>
<tr>
<td>respiratory tract infections</td>
<td>common; on average in every fifth patient during the first month after stroke</td>
<td>early movement, physical therapy, prevention of aspiration, pneumonia, antibiotics, oxygen therapy</td>
<td>needs to be differentiated from pulmonary embolism common cause of stroke‑associated fatalities</td>
</tr>
<tr>
<td>malnutrition</td>
<td>common; on average in every fifth patient</td>
<td>proper nutrition, use of a gastric tube in patients with dysphagia</td>
<td>no need for routine oral use of nutritional supplements</td>
</tr>
<tr>
<td>electrolyte disturbances</td>
<td>common; associated with dehydration, inadequate fluid supply, and diuretic misuse</td>
<td>monitoring of water‑electrolyte balance, adequate oral or parenteral fluid supply</td>
<td>may worsen neurological deficit; consciousnes deficit and lower seizure threshold</td>
</tr>
<tr>
<td>thromboembolic complications (deep vein thrombosis and pulmonary embolism)</td>
<td>deep vein thrombosis manifests clinically in 5% of stroke patients; pulmonary embolism is a common cause of death</td>
<td>early movement, low‑molecular‑weight heparins, antiplatelet drugs, elastic compression stockings</td>
<td>in advanced deep vein thrombosis in patients with hemorrhagic stroke, the use of heparins should be judged by possible risks and benefits</td>
</tr>
<tr>
<td>urinary and fecal incontinence</td>
<td>common; almost half of hospitalized stroke patients</td>
<td>worsening factors must be considered (eg, diuretic misuse); intravesical catheter in some patients for a possibly short period of time</td>
<td></td>
</tr>
<tr>
<td>bedsores — pressure sores</td>
<td>3% of the patients</td>
<td>appropriate care essential: change of position, mattresses for pressure ulcer prevention, adequate nutrition and fluid supply (use of dietary supplement, vitamins), wound dressing, antibiotics, physical therapy, surgical removal of the necrotic tissue</td>
<td></td>
</tr>
<tr>
<td>falls and bone fractures</td>
<td>falls occur in every third patient; 5% of the falls lead to fractures</td>
<td>prevention of falls, use of hip pads</td>
<td></td>
</tr>
<tr>
<td>hemiplegic shoulder pain and shoulder subluxation after stroke</td>
<td>common</td>
<td>physical therapy, analgesics on demand, appropriate placing of the patient and shoulder protection</td>
<td></td>
</tr>
<tr>
<td>emotional disturbances (pathological crying, pseudobulbar affect)</td>
<td>10%–20% of the patients; spontaneous improvement over time</td>
<td>antidepressants, behavioral therapy</td>
<td>can significantly reduce the effectiveness of rehabilitation of cognitive and motor functions</td>
</tr>
<tr>
<td>depression</td>
<td>common; difficult to evaluate in patients with speech disorders</td>
<td>antidepressants, behavioral therapy</td>
<td></td>
</tr>
</tbody>
</table>

 Apart from specific preventive methods, a comprehensive rehabilitation program is crucial for patient recovery and limitation of disability (TABLE 3).

In conclusion, preventive measures—antiplatelet or antithrombotic therapy for patients with AF, carotid interventions, antihypertensive drugs, statins, and lifestyle modifications (including physical activity, diet, and smoking cessation)—can reduce the risk of recurrent stroke by 80%. However, it is still a challenge to translate the efficacy of the interventions reported in clinical trials into everyday clinical practice. So far, studies have failed to translate evidence‑based guidelines into clinical practice and maintain them on daily basis. Therefore, stroke specialists as well as internists and general practitioners will need to cooperate to achieve those targets. This is especially true for Poland where a global study has revealed everyday guideline‑oriented practice to deteriorate along with a decrease in income and general economic decline.
REFERENCES

1 World Health Organization. Cerebrovascular Disorders (Offset Publica-

2 EASTON JD, SAWER JL, ALBERS GW, et al. A Scientific Statement for Health-
care Professionals From the American Heart Association/American Stroke
Association Stroke Council; Council on Cardiovascular Surgery and Anesthe-
sia; Council on Cardiovascular Radiology and Intervention; Council on Car-
diovascular Nursing; and the Interdisciplinary Council on Peripheral Vascu-
lar Disease: The American Academy of Neurology affirms the value of this
statement as an educational tool for neurologists. Definition and Evaluation of

for the 21st century: a statement for healthcare professionals from the
American Heart Association/American Stroke Association. Stroke. 2013; 44:
2064-2089.

4 http://www.who.int/healthinfo/global_burden_disease/estimates_re-

5 National Audit Office. Department of health. Reducing Brain Damage:
Faster access to better stroke care. Report by the Comptroller and auditor

6 FERRI CP, SCHNOEBEN C, KARA L, et al. Prevalence of stroke and related
burden among older people living in Latin America, India and China. J Neurol

7 BURN J, DENNIS M, BAMBORD J, et al. Long-term risk of recurrent stroke
after a first-ever stroke. The Oxfordshire Community Stroke Study. Stroke.

8 ROTHWELL PM, VAWTOW CP. Timing of TAs preceding stroke: time window

9 GILES MF, ROTHWELL PM. Risk of stroke after early transient ischemic
attack: systematic-review and meta-analysis. Lancet Neurol. 2007; 6:
1063-1072.

10 MERWICK A, ALBERS GW, AMAROPORE P, et al. Addition of brain and ca-
rotid imaging to the ABCD2 score to identify patients at early risk of stroke
after transient ischemic attack: a multicentre observational study. Lancet

11 KIYOKURA T, KAMOUCHI M, KUMAI Y, et al. ABCD3 and ABCD1 Score
Assessors to ASCVD Score Score of the Prediction of Short- and Long-Term Risks

in stroke incidence, mortality, case-fatality, severity, and risk factors in Ox-
1295-1303.

13 LUENGO-FERNANDEZ R, GRAY AM, ROTHWELL PM. Effect of urgent treat-
ment for transient ischemic attack and minor stroke on disability and hospi-
tal costs (EXPRESS study): a prospective population-based sequential com-

14 ROTHWELL PM, GILES MF, CHANDRAKATHA A, et al. Effect of urgent treat-
ment of transient ischemic attack and minor stroke on early recurrent stroke
(EXPRESS study): a prospective population-based sequential compar-

15 Lavalette PC, MSEGUEM E, ABBOOD H, et al. A transient ischemic attack
clinic with round-the-clock access (DSST-TIA): feasibility and effects. Lancet

factors for ischemic and intracerebral hemorrhagic stroke in 22 coun-
tries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376:
112-123.

17 JIM J, GALL SL, DEWEY HM, et al. Baseline smoking status and the long-
term risk of death or nonfatal vascular event in people with stroke: a 10-year

smoking cessation: an overview and network meta-analysis. Cochrane Data-

19 HE FJ, LI J, MAOCHEE MA. Effect of longer term modest salt reduction
on blood pressure: Cochrane systematic review and meta-analysis of ran-
domised trials. BMJ. 2013; 346: f1325.

20 MERRICK A, ALBERS GW, AMAROPORE P, et al. Addition of brain and ca-
rotid imaging to the ABCD2 score to identify patients at early risk of stroke
after transient ischemic attack: a multicentre observational study. Lancet

21 KIYOKURA T, KAMOUCHI M, KUMAI Y, et al. ABCD3 and ABCD1 Scores
Assessors to ASCVD Score Score of the Prediction of Short- and Long-Term Risks

in stroke incidence, mortality, case-fatality, severity, and risk factors in Ox-
1295-1303.

23 LUENGO-FERNANDEZ R, GRAY AM, ROTHWELL PM. Effect of urgent treat-
ment for transient ischemic attack and minor stroke on disability and hospi-
tal costs (EXPRESS study): a prospective population-based sequential com-

24 Lavallee PC, MSEGUEM E, ABBOOD H, et al. A transient ischemic attack
clinic with round-the-clock access (DSST-TIA): feasibility and effects. Lancet

in stroke incidence, mortality, case-fatality, severity, and risk factors in Ox-
1295-1303.

factors for ischemic and intracerebral hemorrhagic stroke in 22 coun-
tries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376:
112-123.

27 JIM J, GALL SL, DEWEY HM, et al. Baseline smoking status and the long-
term risk of death or nonfatal vascular event in people with stroke: a 10-year

smoking cessation: an overview and network meta-analysis. Cochrane Data-

29 HE FJ, LI J, MAOCHEE MA. Effect of longer term modest salt reduction
on blood pressure: Cochrane systematic review and meta-analysis of ran-
domised trials. BMJ. 2013; 346: i1325.

30 Hankey GJ. Nutrition and the risk of stroke. Lancet Neurol. 2012; 11:
66-81.

31 Connolly SJ, Eikelboom J, Joyner C, et al.; the AVERROES Steering
Committee and Investigators. Apixaban in patients with atrial fibrillation.

32 MAIER IL, BUELER M, KEMPER P, et al. Risk prediction of very early re-
currence, death and progression after acute ischemic stroke. Eur J Neurol.
2013; 20: 599-604.

33 ROTHWELL PM, VAWTOW CP. Timing of TAs preceding stroke: time window

34 ROTHWELL PM, VAWTOW CP. Timing of TAs preceding stroke: time window

burden among older people living in Latin America, India and China. J Neurol

after a first-ever stroke. The Oxfordshire Community Stroke Study. Stroke.

37 ROTHWELL PM, VAWTOW CP. Timing of TAs preceding stroke: time window

38 ROTHWELL PM, VAWTOW CP. Timing of TAs preceding stroke: time window


ARTYKUŁ POGŁĄDOWY

Profilaktyka udaru niedokrwiennego mózgu w praktyce klinicznej – rola lekarza internisty i lekarza rodzinnego

Maciej Niewada, Anna Członkowska
Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Warszawski Uniwersytet Medyczny, Warszawa
II Klinika Neurologiczna, Instytut Psychiatrii i Neurologii, Warszawa

SŁOWA KLUCZOWE

czynniki ryzyka, następstwa udaru, profilaktyka, przemijający atak niedokrwienny, udar niedokrwienny

STRESZCZENIE

Udar mózgu stanowi ważny problem kliniczny i socjoekonomiczny. Obecnie jest trzecią najczęstszą przyczyną zgonów na świecie. W ciągu roku od zachorowania umiera lub pozostaje niepełnosprawny co trzeci chory. Mimo że śmiertelność wewnątrzszpitalna w przebiegu udaru mózgu się zmniejszyła, to jednak ciągle skuteczna prewencja i kontrola czynników ryzyka ma podstawowe znaczenie w poprawie rokowania i ograniczaniu następstw chorób naczyniowych mózgu. Kluczowe definicje udaru mózgu i przemijającego niedokrwiienia mózgu (transient ischemic attack – TIA) uległy ostatnio modyfikacjom pod wpływem wyników badań neuroobrazujących oraz efektów zastosowania leczenia trombolytycznego. Udar mózgu i TIA nawracają, ale można im skutecznie zapobiegać. Zarówno pacjenci z udarem mózgu, jak i z TIA wymagają szybkiej diagnozy, oceny ryzyka i podjęcia właściwego leczenia profilaktycznego ze względu na wysokie ryzyko nawrotu, udaru mózgu lub zgonu wieńcowego we wczesnym okresie po wystąpieniu TIA. Pięć najczęstszych czynników ryzyka (nadciśnienie tętnicze, palenie papierosów, otyłość, niewłaściwa dieta i brak aktywności fizycznej) odpowiada za 80% przypadków udaru. Profilaktyka udaru mózgu obejmuje zmianę stylu życia oraz specyficzne postępowanie terapeutyczne. W udarze niedokrwiennym mózgu prewencja obejmuje wczesne leczenie (kwasy acetylosalicylowe oraz endarterektomia tętnic szyjnych) oraz długotrwałą profilaktykę, polegającą na leczeniu hipotensyjnym, przeciwpłytkowym, przeciwcarkrempylnym w przypadku chorych z migotaniem przedsiórną oraz stosowaniu statyn i innych leków hipolipemiujących. U chorych po udarze mózgu zwiększone jest ryzyko depresji, otepienia, padaczki i innych powikłań, które także wymagają ukierunkowanego leczenia.